These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34502022)

  • 1. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells.
    Wimmer S; Deloch L; Hader M; Derer A; Grottker F; Weissmann T; Hecht M; Gostian AO; Fietkau R; Frey B; Gaipl US
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
    Grottker F; Gehre S; Reichardt CM; Sengedorj A; Jost T; Rieckmann T; Hecht M; Gostian AO; Frey B; Fietkau R; Gaipl US; Rückert M
    Neoplasia; 2023 Nov; 45():100944. PubMed ID: 37857049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC.
    Meidenbauer J; Wachter M; Schulz SR; Mostafa N; Zülch L; Frey B; Fietkau R; Gaipl US; Jost T
    Front Oncol; 2024; 14():1460150. PubMed ID: 39411143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells.
    Gehre S; Meyer F; Sengedorj A; Grottker F; Reichardt CM; Alomo J; Borgmann K; Frey B; Fietkau R; Rückert M; Gaipl US
    Front Oncol; 2023; 13():981239. PubMed ID: 37152024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
    Dok R; Glorieux M; Bamps M; Nuyts S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma.
    Zhou C; Parsons JL
    Expert Rev Mol Med; 2020 Jul; 22():e3. PubMed ID: 32611474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
    Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
    EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
    Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN
    Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
    Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
    Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation-Induced Dedifferentiation of Head and Neck Cancer Cells Into Cancer Stem Cells Depends on Human Papillomavirus Status.
    Vlashi E; Chen AM; Boyrie S; Yu G; Nguyen A; Brower PA; Hess CB; Pajonk F
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1198-206. PubMed ID: 27026319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Liu T; Ma L; Song L; Yan B; Zhang S; Wang B; Zuo N; Sun X; Deng Y; Ren Q; Li Y; Zhou J; Liu Q; Wei L
    Oral Oncol; 2022 Jun; 129():105858. PubMed ID: 35462155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.